• Select Article Type
  • Abstract Supplements
  • Blood Group Review
  • Call to Arms
  • Hypothesis
  • In Memoriam
  • Interview
  • Introduction
  • Letter to the Editor
  • Short Report
  • abstract
  • Abstracts
  • Article
  • book-review
  • case-report
  • case-study
  • Clinical Practice
  • Commentary
  • Conference Presentation
  • conference-report
  • congress-report
  • Correction
  • critical-appraisal
  • Editorial
  • Editorial Comment
  • Erratum
  • Events
  • Letter
  • Letter to Editor
  • mini-review
  • minireview
  • News
  • non-scientific
  • Obituary
  • original-paper
  • original-report
  • Original Research
  • Pictorial Review
  • Position Paper
  • Practice Report
  • Preface
  • Preliminary report
  • Product Review
  • rapid-communication
  • Report
  • research-article
  • Research Communicate
  • research-paper
  • Research Report
  • Review
  • review -article
  • review-article
  • review-paper
  • Review Paper
  • Sampling Methods
  • Scientific Commentary
  • short-communication
  • short-report
  • Student Essay
  • Varia
  • Welome
  • Select Journal
  • Immunohematology


Review | 09-October-2019

The Vel blood group system: a review

The blood group antigen Vel has been one of immunohematology’s greatest enigmas: the variation in antigen strength from one individual to another, the property of anti-Vel to readily hemolyze Vel+ red blood cells (RBCs), and the difficulty to screen for sufficient numbers of Vel– blood donors had made Vel a tough nut to crack. In 2013, a small, previously unknown protein called small integral membrane protein 1 (SMIM1) was identified on the RBC by three independent research groups

Jill R. Storry, Thierry Peyrard

Immunohematology, Volume 33 , ISSUE 2, 56–59

Case report | 12-March-2020

Role for serial prenatal anti-Vel quantitative serologic monitoring with 2-ME serum treatment during pregnancy: case report

Anti-Vel is an uncommon antibody to a high-prevalence antigen. Its clinical significance and management in the prenatal setting are not well characterized. We present a case that demonstrates the utility of serial prenatal anti-Vel quantitative serologic monitoring with 2-ME serum treatment during pregnancy. The patient is a 23-year-old Hispanic woman with history of prior pregnancy and prior transfusion who was discovered to have an antibody to the high-prevalence Vel antigen in the first

Walter J. Linz, Judith T. Fueger, Steven Allen, Susan T. Johnson

Immunohematology, Volume 26 , ISSUE 1, 8–10

Article | 16-October-2019

Anti-Vel alloimmunization and severe hemolytic disease of the fetus and newborn

The Vel red blood cell (RBC) antigen was first described in 1952.1 The antigen is ubiquitous in the general population, with only 0.04 percent of Caucasian individuals failing to exhibit expression.2 Only rare cases of anti-Vel–associated mild-to-moderate hemolytic disease of the fetus and newborn (HDFN) have been previously reported.3–7 The neonatal manifestation of HDFN in these cases was limited to hyperbilirubinemia requiring only phototherapy. No case of fetal anemia requiring prenatal

K.J. Moise, Y. Morales, M.F. Bertholf, S.N. Rossmann, Y. Bai

Immunohematology, Volume 33 , ISSUE 4, 152–154

Review | 16-October-2019

Clinical significance of antibodies to antigens in the Raph, John Milton Hagen, I, Globoside, Gill, Rh-associated glycoprotein, FORS, JR, LAN, Vel, CD59, and Augustine blood group systems

This article reviews information on the clinical significance of antibodies to antigens in the Raph, John Milton Hagen, I, Globoside, Gill, Rh-associated glycoprotein, FORS, JR, LAN, Vel, CD59, and Augustine blood group systems. Antibodies to many of the antigens in these groups are rarely encountered because of the high prevalence of the associated antigens in most populations. For many of these antibodies, the clinical significance—that is, the potential to cause reduced survival of

Mostafa Moghaddam, Amir Ali Naghi

Immunohematology, Volume 34 , ISSUE 3, 85–90

Article | 17-November-2020

Elimination of a requirement for Vel-negative red blood cells and successful transfusion following chromium-51 survival study

A 42-year-old woman presented with anemia and complex serologic test results that included a requirement for Vel-negative red blood cells (RBCs). Rare Vel-negative units were located and transfused, but her anemia worsened. As further serologic evaluation was inconclusive, an in vivo recovery study with Vel-positive RBCs was performed. Normal 24-hour recovery of these cells resulted in removal of the Vel-negative antigen restriction and successful transfusion of the patient. Resolution of the

Richard J. Davey, Jo Lynn Procter

Immunohematology, Volume 11 , ISSUE 2, 39–42

Article | 30-November-2020

Misidentification of anti-Vel due to inappropriate use of prewarming and adsorption techniques

the reactivity at the IAT. The patient was transfused with two units of washed RBCs and died 6 to 8 hours later. Retrospective testing in our laboratory detected anti-Vel in both pretransfusion and posttransfusion samples. The pretransfusion serum was hemolytic when tested in LISS or with papain-treated RBCs. Weak reactivity (1+) was observed at the IAT. EDTA-treated serum (to prevent C‘-mediated hemolysis) was strongly reactive (3+s) with Vel+ RBCs but compatible with 10 examples of Vel

Jill Storry, Delores Mallory

Immunohematology, Volume 10 , ISSUE 3, 83–86

Article | 13-April-2020

Problems highlighted when using anticoagulated samples in the standard tube low ionic strength antiglobulin test

-activating anti-Vel. In all three cases, the coincidental referral and investigation of both clotted and anticoagulated samples led to the discrepancy in serum and plasma test results becoming apparent. Potential errors in selection of suitable blood for transfusion and appropriate antenatal management were avoided by correct identification of the antibodies present using the clotted samples.

Amanda J Sweeney

Immunohematology, Volume 22 , ISSUE 2, 72–77

Letter to Editor | 14-March-2020

To the Editors: Anti-Vel and cold-reactive autoantibody

Joan L Maurer, Sandra Taddie Nance

Immunohematology, Volume 26 , ISSUE 4, 187–187

Letter to Editor | 14-October-2020

Letter to the Editors: Vel– donors in Yugoslavia

Milan Djokic, Andrija Kuzmanovic, Zivko Budisin, Snezana Srzentic, Joyce Poole, Radica Stevanovic

Immunohematology, Volume 19 , ISSUE 2, 59–59

Article | 16-November-2020

Effect of pronase on highincidence blood group antigens and the prevalence of antibodies to pronase-treated erythrocytes

Cromer and Lutheran blood group systems and the JMH antigen were sensitive to pronase treatment of RBCs. Antigens in the Dombrock blood group system and Sc1 were either sensitive to or markedly weakened by pronase treatment of RBCs. The following high-incidence antigens were resistant to treatment of RBCs with pronase: AnWj, Ata, Coa, Co3, Dib, EnaFR, Era, Fy3, Jk3, Jra, k, Kpb, Jsb, K14, Lan, Oka, Rh17, U, Vel, and Wrb. Over half of the serum samples from normal blood donors contained antibodies to

Marion E. Reid, Carole A. Green, Jack Hoffer, Ragnhild Øyen

Immunohematology, Volume 12 , ISSUE 4, 139–142

Article | 06-December-2020

Six monoclonal antibodies to the CD59 antigen

, including Rhnull; Oh; ii; Ko; FY:-1,-2,-3; JK:-1,-2,-3; S-s-U-; p; CO:-1,-2; Yt(a-); Jr(a-); Vel-; At(a-); Cr(a-); GE:-2,-3; Wr(a+b+); MkMk; Jo(a-); and Lan-. 2-aminoethylisotbiouronium bromide treatment of erythrocytes destroyed blotting and serologic reactivity of all six antibodies. Pronase treatment reduced serologic reactivity and blotting ability of all antibodies except BRlC 229. Reactivity of all six antibodies was reduced with RBCs from paroxysmal nocturnal hemoglobinuria patients. Flow

Jennifer A. Bryant, Anne Fletcher, Fang Fang Yuan

Immunohematology, Volume 9 , ISSUE 3, 68–73

No Record Found..
Page Actions